

Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	8.2	122.3	(58.5-224.9)	Male	17	5.3	318.8	(185.6-510.4)
Female	3	3.1	nc	(nc-nc)	Female	4	4.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.5	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
Female	37	37.9	97.5	(68.7-134.4)	Female	6	4.4	137.9	(50.3-300.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	2.0	nc	(nc-nc)
Male	11	8.6	127.4	(63.5-228.0)	<u>Ovary</u>				
Female	2	8.3	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.2	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	41	27.7	148.2	(106.3-201.1)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.0	nc	(nc-nc)
Male	4	5.0	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Female	5	3.0	169.0	(54.5-394.3)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.8	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
<u>Leukemia</u>					Female	7	6.7	105.1	(42.1-216.6)
Male	2	3.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.4	nc	(nc-nc)	Female	12	9.2	131.0	(67.6-228.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	3.2	nc	(nc-nc)	Male	123	108.7	113.1	(94.0-135.0)
Female	1	1.1	nc	(nc-nc)	Female	104	121.4	85.7	(70.0-103.8)
<u>Lung and Bronchus</u>									
Male	11	15.0	73.6	(36.7-131.6)					
Female	10	17.2	58.1	(27.8-106.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newburyport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	21.3	98.8	(61.1-151.0)	Male	20	14.0	143.4	(87.5-221.4)
Female	5	8.9	56.0	(18.0-130.7)	Female	15	11.9	125.7	(70.3-207.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.1	nc	(nc-nc)	Male	1	4.6	nc	(nc-nc)
Female	3	3.8	nc	(nc-nc)	Female	5	4.2	119.3	(38.4-278.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.8	nc	(nc-nc)	Male	14	12.4	113.3	(61.9-190.1)
Female	96	99.6	96.4	(78.1-117.7)	Female	9	12.1	74.2	(33.8-140.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	3.0	nc	(nc-nc)	Male	9	11.1	81.1	(37.0-154.0)
<u>Colon / Rectum</u>					Female	6	5.5	110.1	(40.2-239.6)
Male	25	22.9	109.1	(70.6-161.1)	<u>Ovary</u>				
Female	21	24.9	84.4	(52.2-129.0)	Female	3	8.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	5.7	nc	(nc-nc)	Male	9	8.2	110.0	(50.2-208.9)
Female	0	1.8	nc	(nc-nc)	Female	8	9.3	86.2	(37.1-169.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.4	nc	(nc-nc)	Male	90	72.0	125.0	(100.5-153.6)
Female	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	5.1	nc	(nc-nc)
Male	6	13.2	45.4	(16.6-98.9)	Female	3	3.5	nc	(nc-nc)
Female	3	8.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.5	nc	(nc-nc)
Male	1	3.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.2	nc	(nc-nc)	Male	12	5.7	212.2	(109.5-370.7)
<u>Leukemia</u>					Female	21	16.7	126.0	(78.0-192.6)
Male	11	8.5	129.2	(64.4-231.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	6.9	nc	(nc-nc)	Female	26	23.6	110.3	(72.1-161.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	8.2	60.7	(19.6-141.6)	Male	282	284.3	99.2	(87.9-111.5)
Female	3	3.0	nc	(nc-nc)	Female	295	331.1	89.1	(79.2-99.9)
<u>Lung and Bronchus</u>									
Male	25	38.2	65.4	(42.3-96.5)					
Female	36	47.5	75.8	(53.1-104.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	111	102.0	108.8	(89.5-131.0)	Male	68	63.4	107.2	(83.3-135.9)
Female	46	35.6	129.1	(94.5-172.2)	Female	68	49.4	137.8	(107.0-174.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	22	18.3	120.3	(75.4-182.2)	Male	28	20.5	136.3	(90.5-197.0)
Female	18	16.3	110.2	(65.3-174.2)	Female	16	16.7	96.1	(54.9-156.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	3.5	nc	(nc-nc)	Male	64	56.3	113.6	(87.5-145.1)
Female	447	399.4	111.9	(101.8-122.8)	Female	54	48.9	110.4	(82.9-144.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	13.0	61.7	(26.6-121.5)	Male	28	45.7	61.3	(40.7-88.6)
<u>Colon / Rectum</u>					Female	29	21.8	133.1	(89.1-191.1)
Male	100	103.9	96.2	(78.3-117.0)	<u>Ovary</u>				
Female	82	102.1	80.3	(63.9-99.7)	Female	47	34.3	136.9	(100.6-182.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	25.1	35.9	(16.4-68.1)	Male	30	37.1	80.8	(54.5-115.3)
Female	6	7.0	85.5	(31.2-186.0)	Female	51	37.4	136.3	(101.5-179.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	10	6.6	151.3	(72.4-278.2)	Male	332	294.3	112.8	(101.0-125.6)
Female	8	5.9	135.1	(58.2-266.2)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	25	23.5	106.3	(68.8-156.9)
Male	51	56.0	91.1	(67.8-119.8)	Female	11	14.4	76.5	(38.1-136.9)
Female	27	31.8	84.8	(55.9-123.4)	<u>Testis</u>				
<u>Larynx</u>					Male	13	11.8	110.4	(58.7-188.9)
Male	9	14.5	62.1	(28.3-117.9)	<u>Thyroid</u>				
Female	0	4.4	nc	(nc-nc)	Male	32	24.0	133.5	(91.3-188.5)
<u>Leukemia</u>					Female	84	72.4	116.0	(92.5-143.6)
Male	34	40.0	85.0	(58.9-118.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	27	29.0	93.0	(61.3-135.3)	Female	87	91.1	95.5	(76.5-117.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	22	34.2	64.3	(40.3-97.3)	Male	1175	1258.9	93.3	(88.1-98.8)
Female	9	11.9	75.5	(34.4-143.2)	Female	1380	1336.2	103.3	(97.9-108.9)
<u>Lung and Bronchus</u>									
Male	113	176.1	64.2	(52.9-77.1)					
Female	148	185.6	79.7	(67.4-93.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norfolk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	13.2	60.8	(26.2-119.8)	Male	24	9.4	255.4	(163.6-380.0)
Female	1	2.8	nc	(nc-nc)	Female	4	4.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.9	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	6	8.3	72.4	(26.5-157.7)
Female	41	39.1	105.0	(75.3-142.4)	Female	2	4.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	6	7.7	77.4	(28.3-168.6)
<u>Colon / Rectum</u>					Female	1	2.0	nc	(nc-nc)
Male	9	15.1	59.6	(27.2-113.1)	<u>Ovary</u>				
Female	6	8.4	71.8	(26.2-156.3)	Female	1	3.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.8	131.6	(42.4-307.2)	Male	2	5.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	38	47.6	79.8	(56.5-109.5)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	3.3	150.2	(48.4-350.5)
Male	12	9.1	131.3	(67.8-229.4)	Female	0	1.2	nc	(nc-nc)
Female	4	2.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	2.4	nc	(nc-nc)
Male	3	2.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	4.4	nc	(nc-nc)
<u>Leukemia</u>					Female	10	7.7	129.9	(62.2-239.0)
Male	5	5.7	87.8	(28.3-204.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.5	nc	(nc-nc)	Female	7	9.1	76.9	(30.8-158.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	5.6	nc	(nc-nc)	Male	155	189.1	82.0	(69.6-95.9)
Female	1	1.0	nc	(nc-nc)	Female	105	121.3	86.6	(70.8-104.8)
<u>Lung and Bronchus</u>									
Male	16	24.4	65.7	(37.5-106.6)					
Female	13	15.2	85.4	(45.4-146.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	16.6	114.5	(68.9-178.8)	Male	4	10.3	nc	(nc-nc)
Female	10	6.3	159.8	(76.5-293.9)	Female	6	8.0	74.9	(27.4-163.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.9	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	10	9.1	110.5	(52.9-203.2)
Female	50	63.9	78.2	(58.0-103.1)	Female	7	8.2	85.3	(34.2-175.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.0	nc	(nc-nc)	Male	10	7.3	137.0	(65.6-251.9)
<u>Colon / Rectum</u>					Female	6	3.6	166.5	(60.8-362.3)
Male	24	16.6	144.4	(92.5-214.9)	<u>Ovary</u>				
Female	17	17.6	96.4	(56.1-154.4)	Female	7	5.6	125.1	(50.1-257.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	4.0	172.9	(69.3-356.2)	Male	0	6.0	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	7	6.6	106.0	(42.5-218.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	38	47.2	80.4	(56.9-110.4)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	3.8	131.6	(42.4-307.2)
Male	7	9.0	78.1	(31.3-160.9)	Female	2	2.5	nc	(nc-nc)
Female	3	5.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.9	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	0.7	nc	(nc-nc)	Male	6	3.8	157.6	(57.5-343.0)
<u>Leukemia</u>					Female	11	10.9	100.7	(50.2-180.2)
Male	5	6.4	77.6	(25.0-181.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.9	nc	(nc-nc)	Female	12	14.5	83.0	(42.8-145.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	5.6	179.6	(86.0-330.3)	Male	203	203.2	99.9	(86.6-114.6)
Female	3	2.0	nc	(nc-nc)	Female	209	220.9	94.6	(82.2-108.4)
<u>Lung and Bronchus</u>									
Male	28	29.0	96.7	(64.2-139.8)					
Female	41	32.1	127.8	(91.7-173.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	28.8	111.2	(76.1-157.0)	Male	20	18.9	105.8	(64.6-163.4)
Female	6	11.4	52.6	(19.2-114.5)	Female	15	16.2	92.4	(51.7-152.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.8	103.8	(37.9-225.9)	Male	6	6.0	100.3	(36.6-218.2)
Female	6	5.2	115.5	(42.2-251.3)	Female	8	5.4	149.1	(64.2-293.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	20	16.8	118.8	(72.5-183.4)
Female	128	131.1	97.6	(81.5-116.1)	Female	14	15.8	88.5	(48.4-148.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	4.4	nc	(nc-nc)	Male	11	14.5	76.0	(37.9-136.0)
<u>Colon / Rectum</u>					Female	1	7.0	nc	(nc-nc)
Male	24	31.6	76.0	(48.7-113.0)	<u>Ovary</u>				
Female	37	33.7	109.7	(77.2-151.2)	Female	11	11.2	98.2	(49.0-175.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	7.3	108.9	(46.9-214.7)	Male	6	10.8	55.5	(20.3-120.8)
Female	0	2.2	nc	(nc-nc)	Female	12	12.0	99.7	(51.5-174.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.2	nc	(nc-nc)	Male	90	87.7	102.6	(82.5-126.1)
Female	5	1.9	266.4	(85.8-621.6)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	6.9	72.7	(23.4-169.7)
Male	12	17.3	69.5	(35.9-121.5)	Female	7	4.7	148.9	(59.6-306.8)
Female	7	10.3	67.8	(27.2-139.8)	<u>Testis</u>				
<u>Larynx</u>					Male	5	4.3	116.5	(37.5-271.9)
Male	0	4.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.4	nc	(nc-nc)	Male	12	8.1	148.8	(76.8-259.9)
<u>Leukemia</u>					Female	22	24.5	89.6	(56.2-135.7)
Male	14	12.0	116.8	(63.8-195.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	9.3	117.9	(58.8-210.9)	Female	25	29.0	86.2	(55.8-127.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	10.5	56.9	(20.8-123.8)	Male	351	374.1	93.8	(84.3-104.2)
Female	3	3.8	nc	(nc-nc)	Female	397	434.7	91.3	(82.6-100.8)
<u>Lung and Bronchus</u>									
Male	37	49.2	75.1	(52.9-103.6)					
Female	49	59.1	82.9	(61.3-109.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Attleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	22.6	124.0	(82.4-179.2)	Male	15	16.3	91.8	(51.3-151.4)
Female	8	9.1	87.9	(37.8-173.2)	Female	20	14.3	139.4	(85.1-215.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.3	112.5	(41.1-245.0)	Male	8	5.2	154.7	(66.6-304.7)
Female	6	4.7	127.6	(46.6-277.8)	Female	6	4.4	136.8	(50.0-297.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	16	14.5	110.4	(63.1-179.3)
Female	117	116.3	100.6	(83.2-120.5)	Female	16	13.2	121.1	(69.1-196.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	4.2	nc	(nc-nc)	Male	14	13.3	105.5	(57.6-177.0)
<u>Colon / Rectum</u>					Female	3	6.0	nc	(nc-nc)
Male	31	26.4	117.2	(79.6-166.4)	<u>Ovary</u>				
Female	22	27.4	80.3	(50.3-121.6)	Female	4	9.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	6.4	140.7	(64.2-267.0)	Male	11	9.0	122.0	(60.8-218.4)
Female	1	1.8	nc	(nc-nc)	Female	11	9.5	115.5	(57.6-206.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.2	nc	(nc-nc)	Male	79	78.8	100.2	(79.3-124.9)
Female	1	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	5.7	nc	(nc-nc)
Male	12	15.9	75.6	(39.0-132.0)	Female	4	3.8	nc	(nc-nc)
Female	9	8.9	100.8	(46.0-191.3)	<u>Testis</u>				
<u>Larynx</u>					Male	5	4.5	110.1	(35.5-257.0)
Male	3	3.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.2	nc	(nc-nc)	Male	6	8.0	74.6	(27.2-162.4)
<u>Leukemia</u>					Female	25	23.8	105.2	(68.0-155.2)
Male	5	10.1	49.3	(15.9-115.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	7.9	nc	(nc-nc)	Female	21	25.8	81.4	(50.3-124.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	9.3	96.4	(44.0-183.0)	Male	334	324.4	103.0	(92.2-114.6)
Female	3	3.2	nc	(nc-nc)	Female	350	374.5	93.5	(83.9-103.8)
<u>Lung and Bronchus</u>									
Male	39	41.7	93.6	(66.6-128.0)					
Female	41	48.6	84.3	(60.5-114.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	5.3	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	0	2.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
Female	16	20.7	77.2	(44.1-125.5)	Female	4	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.7	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.1	nc	(nc-nc)
Male	6	5.6	106.2	(38.8-231.2)	<u>Ovary</u>				
Female	5	5.3	94.2	(30.4-219.8)	Female	2	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.4	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	18	16.1	111.9	(66.3-176.8)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.3	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.8	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.5	nc	(nc-nc)	Female	6	4.6	130.4	(47.6-283.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.0	nc	(nc-nc)	Male	71	69.0	102.9	(80.4-129.8)
Female	2	0.6	nc	(nc-nc)	Female	63	69.2	91.0	(69.9-116.4)
<u>Lung and Bronchus</u>									
Male	10	9.6	104.1	(49.9-191.5)					
Female	6	9.7	61.6	(22.5-134.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	16.2	86.7	(47.3-145.4)	Male	11	10.8	101.5	(50.6-181.7)
Female	7	5.6	125.4	(50.2-258.3)	Female	9	8.5	105.8	(48.3-200.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.3	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
Female	5	2.7	186.0	(59.9-434.1)	Female	1	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	10	9.6	104.2	(49.9-191.6)
Female	82	71.7	114.4	(91.0-142.0)	Female	4	8.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.4	nc	(nc-nc)	Male	3	8.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	3.7	nc	(nc-nc)
Male	14	17.5	79.9	(43.6-134.0)	<u>Ovary</u>				
Female	14	16.4	85.3	(46.6-143.2)	Female	4	6.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	4.3	185.6	(79.9-365.7)	Male	6	6.2	97.1	(35.4-211.3)
Female	0	1.1	nc	(nc-nc)	Female	7	5.7	122.3	(49.0-252.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	50	52.1	95.9	(71.2-126.4)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.9	nc	(nc-nc)
Male	10	10.1	98.9	(47.4-182.0)	Female	0	2.3	nc	(nc-nc)
Female	3	5.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.3	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	6	4.6	129.7	(47.4-282.3)
<u>Leukemia</u>					Female	18	13.7	131.6	(78.0-208.0)
Male	8	6.7	119.5	(51.5-235.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.6	nc	(nc-nc)	Female	18	16.2	111.0	(65.7-175.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	6.2	80.8	(26.0-188.5)	Male	189	215.9	87.6	(75.5-101.0)
Female	2	1.9	nc	(nc-nc)	Female	219	227.9	96.1	(83.8-109.7)
<u>Lung and Bronchus</u>									
Male	15	29.2	51.4	(28.8-84.8)					
Female	24	30.8	78.0	(50.0-116.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	41	29.7	138.3	(99.2-187.6)	Male	13	18.8	69.3	(36.9-118.5)
Female	11	11.4	96.9	(48.3-173.4)	Female	9	15.9	56.7	(25.9-107.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.5	108.5	(39.6-236.1)	Male	1	6.1	nc	(nc-nc)
Female	4	5.4	nc	(nc-nc)	Female	7	5.4	130.0	(52.1-267.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.1	nc	(nc-nc)	Male	18	16.8	107.3	(63.6-169.6)
Female	166	127.3	130.4	(111.3-151.8)	Female	16	15.8	101.5	(58.0-164.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	4.0	123.9	(39.9-289.2)	Male	15	13.9	107.9	(60.4-178.0)
<u>Colon / Rectum</u>					Female	4	7.1	nc	(nc-nc)
Male	29	30.5	95.2	(63.7-136.7)	<u>Ovary</u>				
Female	37	32.5	113.7	(80.0-156.7)	Female	17	11.1	152.6	(88.8-244.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	7.5	106.2	(45.7-209.3)	Male	10	11.0	91.1	(43.6-167.5)
Female	4	2.2	nc	(nc-nc)	Female	11	11.9	92.4	(46.1-165.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.2	nc	(nc-nc)	Male	54	91.4	59.1	(44.4-77.1)
Female	1	2.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	6.9	86.7	(31.7-188.8)
Male	12	16.9	71.1	(36.7-124.1)	Female	4	4.6	nc	(nc-nc)
Female	9	10.2	88.4	(40.4-167.9)	<u>Testis</u>				
<u>Larynx</u>					Male	7	4.0	175.4	(70.3-361.5)
Male	2	4.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	1.5	nc	(nc-nc)	Male	4	7.4	nc	(nc-nc)
<u>Leukemia</u>					Female	10	23.3	42.9	(20.6-79.0)
Male	13	11.8	110.5	(58.8-188.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	9.3	75.2	(30.1-154.9)	Female	44	29.7	148.2	(107.7-198.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	10.5	47.7	(15.4-111.3)	Male	314	377.7	83.1	(74.2-92.9)
Female	3	3.9	nc	(nc-nc)	Female	454	428.0	106.1	(96.5-116.3)
<u>Lung and Bronchus</u>									
Male	44	51.8	84.9	(61.7-114.0)					
Female	44	59.0	74.6	(54.2-100.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	16.2	129.5	(80.2-198.0)	Male	12	10.7	111.6	(57.6-195.0)
Female	7	5.8	121.1	(48.5-249.4)	Female	8	8.1	98.2	(42.3-193.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.2	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	Female	5	2.7	185.0	(59.6-431.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	10	9.5	104.7	(50.1-192.6)
Female	73	66.0	110.6	(86.7-139.0)	Female	5	8.0	62.5	(20.2-145.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.2	nc	(nc-nc)	Male	8	8.3	96.4	(41.5-190.0)
<u>Colon / Rectum</u>					Female	2	3.6	nc	(nc-nc)
Male	11	17.9	61.6	(30.7-110.2)	<u>Ovary</u>				
Female	15	16.8	89.3	(49.9-147.2)	Female	3	5.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	4.2	190.9	(82.2-376.3)	Male	6	6.2	97.4	(35.6-212.1)
Female	0	1.1	nc	(nc-nc)	Female	6	6.0	99.5	(36.3-216.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	50	50.3	99.5	(73.8-131.1)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.9	nc	(nc-nc)
Male	10	10.0	100.4	(48.0-184.6)	Female	2	2.3	nc	(nc-nc)
Female	4	5.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.3	nc	(nc-nc)
Male	0	2.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
<u>Leukemia</u>					Female	8	12.2	65.8	(28.3-129.6)
Male	10	6.6	151.8	(72.7-279.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	4.7	149.7	(60.0-308.5)	Female	15	14.9	100.7	(56.3-166.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.9	nc	(nc-nc)	Male	196	212.6	92.2	(79.7-106.1)
Female	2	1.9	nc	(nc-nc)	Female	209	219.2	95.3	(82.8-109.2)
<u>Lung and Bronchus</u>									
Male	13	28.6	45.4	(24.1-77.6)					
Female	30	30.3	98.9	(66.7-141.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	15.9	113.5	(67.2-179.4)	Male	9	10.7	84.1	(38.4-159.7)
Female	5	6.3	79.7	(25.7-186.1)	Female	8	8.9	89.7	(38.6-176.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.2	nc	(nc-nc)	Male	8	3.4	232.6	(100.2-458.4)
Female	2	3.0	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	9	9.4	95.6	(43.6-181.5)
Female	58	70.6	82.1	(62.4-106.2)	Female	12	8.7	137.9	(71.2-240.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.4	nc	(nc-nc)	Male	8	8.4	94.9	(40.9-187.1)
<u>Colon / Rectum</u>					Female	2	3.8	nc	(nc-nc)
Male	9	17.6	51.1	(23.3-97.0)	<u>Ovary</u>				
Female	26	18.3	142.1	(92.8-208.3)	Female	4	6.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	4.3	nc	(nc-nc)	Male	5	6.1	81.9	(26.4-191.2)
Female	1	1.2	nc	(nc-nc)	Female	7	6.5	106.9	(42.8-220.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.2	nc	(nc-nc)	Male	50	51.9	96.4	(71.5-127.1)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	3.9	129.1	(41.6-301.2)
Male	14	10.1	138.9	(75.9-233.0)	Female	3	2.6	nc	(nc-nc)
Female	6	5.6	107.1	(39.1-233.1)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.3	nc	(nc-nc)
Male	3	2.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
<u>Leukemia</u>					Female	12	13.6	88.2	(45.5-154.1)
Male	4	6.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.2	95.6	(30.8-223.1)	Female	18	15.4	116.7	(69.1-184.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	6.1	nc	(nc-nc)	Male	194	213.6	90.8	(78.5-104.5)
Female	2	2.1	nc	(nc-nc)	Female	224	236.5	94.7	(82.7-108.0)
<u>Lung and Bronchus</u>									
Male	27	28.6	94.5	(62.3-137.6)					
Female	30	32.3	93.0	(62.7-132.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.9	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	4	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	12	13.9	86.6	(44.7-151.3)	Female	1	1.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.7	nc	(nc-nc)
Male	3	4.1	nc	(nc-nc)	<u>Ovary</u>				
Female	2	3.4	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	12.6	39.8	(12.8-92.8)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.9	nc	(nc-nc)
Male	3	2.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	3	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.5	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	0	2.6	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.0	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.4	nc	(nc-nc)	Male	35	50.7	69.1	(48.1-96.1)
Female	0	0.4	nc	(nc-nc)	Female	41	45.5	90.1	(64.7-122.3)
<u>Lung and Bronchus</u>									
Male	4	6.8	nc	(nc-nc)					
Female	4	6.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	18.7	69.6	(37.0-119.0)	Male	14	12.6	111.3	(60.8-186.7)
Female	9	6.0	149.6	(68.3-284.0)	Female	16	9.0	176.8	(101.0-287.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.9	128.6	(41.5-300.2)	Male	4	4.0	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	7	11.1	62.9	(25.2-129.5)
Female	77	74.2	103.7	(81.8-129.6)	Female	12	8.6	138.8	(71.6-242.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.5	nc	(nc-nc)	Male	8	10.0	80.2	(34.5-158.1)
<u>Colon / Rectum</u>					Female	2	3.9	nc	(nc-nc)
Male	24	20.6	116.6	(74.7-173.4)	<u>Ovary</u>				
Female	22	17.7	124.6	(78.1-188.7)	Female	8	6.4	126.0	(54.2-248.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	5.0	99.4	(32.0-231.9)	Male	9	7.2	125.6	(57.3-238.5)
Female	1	1.2	nc	(nc-nc)	Female	10	6.2	161.2	(77.2-296.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.5	nc	(nc-nc)	Male	54	62.3	86.7	(65.1-113.1)
Female	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	4.6	109.9	(35.4-256.4)
Male	15	11.9	126.0	(70.5-207.8)	Female	4	2.5	nc	(nc-nc)
Female	7	5.8	121.3	(48.6-249.9)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.8	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.8	nc	(nc-nc)	Male	6	5.5	109.1	(39.8-237.4)
<u>Leukemia</u>					Female	15	14.3	104.6	(58.5-172.6)
Male	11	7.9	139.4	(69.5-249.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	5.1	118.2	(43.1-257.2)	Female	24	16.9	141.9	(90.9-211.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	7.2	83.3	(30.4-181.3)	Male	248	253.3	97.9	(86.1-110.9)
Female	1	2.1	nc	(nc-nc)	Female	272	241.1	112.8	(99.8-127.1)
<u>Lung and Bronchus</u>									
Male	34	33.6	101.1	(70.0-141.3)					
Female	30	32.1	93.4	(63.0-133.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norwell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	13.4	104.7	(57.2-175.6)	Male	9	8.5	105.8	(48.3-200.9)
Female	4	4.5	nc	(nc-nc)	Female	16	6.2	258.2	(147.5-419.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	2.4	287.0	(115.0-591.3)	Male	1	2.7	nc	(nc-nc)
Female	4	2.0	nc	(nc-nc)	Female	6	2.1	289.9	(105.9-631.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	5	7.5	66.7	(21.5-155.7)
Female	54	51.8	104.2	(78.3-136.0)	Female	9	6.1	146.9	(67.0-278.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.7	nc	(nc-nc)	Male	5	6.3	80.0	(25.8-186.7)
<u>Colon / Rectum</u>					Female	5	2.7	182.7	(58.9-426.3)
Male	11	14.1	78.0	(38.9-139.7)	<u>Ovary</u>				
Female	11	13.0	84.5	(42.1-151.2)	Female	6	4.4	137.9	(50.4-300.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.3	nc	(nc-nc)	Male	7	4.9	142.2	(57.0-292.9)
Female	0	0.9	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.8	nc	(nc-nc)	Male	37	38.4	96.3	(67.8-132.7)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.1	nc	(nc-nc)
Male	4	7.6	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
Female	4	4.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.5	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
<u>Leukemia</u>					Female	4	9.1	nc	(nc-nc)
Male	5	5.3	94.1	(30.3-219.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.6	nc	(nc-nc)	Female	16	11.4	139.8	(79.8-227.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	4.6	152.0	(60.9-313.1)	Male	153	166.9	91.7	(77.7-107.4)
Female	1	1.5	nc	(nc-nc)	Female	182	169.8	107.2	(92.2-123.9)
<u>Lung and Bronchus</u>									
Male	13	23.2	56.1	(29.8-95.9)					
Female	14	23.8	58.9	(32.1-98.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	32.4	34.0	(16.9-60.8)	Male	36	20.4	176.8	(123.8-244.7)
Female	7	13.2	53.0	(21.3-109.3)	Female	20	17.3	115.8	(70.7-178.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	6.0	99.9	(36.5-217.5)	Male	8	6.5	123.6	(53.2-243.5)
Female	8	5.5	144.4	(62.2-284.5)	Female	7	6.0	116.7	(46.8-240.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.1	nc	(nc-nc)	Male	18	18.0	100.2	(59.3-158.3)
Female	143	136.3	104.9	(88.4-123.6)	Female	19	17.6	108.2	(65.1-169.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	4.4	114.9	(37.0-268.0)	Male	16	14.3	112.2	(64.1-182.3)
<u>Colon / Rectum</u>					Female	7	7.6	92.5	(37.1-190.6)
Male	49	33.3	147.2	(108.9-194.6)	<u>Ovary</u>				
Female	51	37.4	136.4	(101.6-179.4)	Female	11	11.9	92.4	(46.1-165.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	7.8	102.6	(44.2-202.1)	Male	20	11.6	172.3	(105.2-266.1)
Female	3	2.5	nc	(nc-nc)	Female	20	13.8	145.1	(88.6-224.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.4	nc	(nc-nc)	Male	78	87.7	88.9	(70.3-110.9)
Female	3	2.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	7.5	120.8	(55.1-229.3)
Male	12	17.7	68.0	(35.1-118.7)	Female	4	5.2	nc	(nc-nc)
Female	15	11.2	134.2	(75.1-221.4)	<u>Testis</u>				
<u>Larynx</u>					Male	9	4.7	191.1	(87.2-362.7)
Male	6	4.5	134.1	(49.0-292.0)	<u>Thyroid</u>				
Female	3	1.5	nc	(nc-nc)	Male	13	8.0	162.6	(86.5-278.1)
<u>Leukemia</u>					Female	25	24.3	103.0	(66.6-152.0)
Male	14	12.9	108.5	(59.2-182.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	10.4	105.7	(52.7-189.2)	Female	32	30.2	106.0	(72.5-149.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	12	10.5	114.1	(58.9-199.4)	Male	430	395.7	108.7	(98.6-119.5)
Female	3	4.2	nc	(nc-nc)	Female	522	469.5	111.2	(101.8-121.1)
<u>Lung and Bronchus</u>									
Male	58	55.7	104.0	(79.0-134.5)					
Female	93	68.1	136.5	(110.2-167.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oak Bluffs

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	8.0	124.5	(59.6-229.0)	Male	8	4.9	162.6	(70.0-320.4)
Female	1	2.3	nc	(nc-nc)	Female	7	3.0	236.6	(94.8-487.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	24	24.2	99.3	(63.6-147.7)	Female	1	3.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.8	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.3	nc	(nc-nc)
Male	8	7.7	104.0	(44.8-204.9)	<u>Ovary</u>				
Female	5	6.6	76.1	(24.5-177.5)	Female	2	2.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.0	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	16	23.0	69.5	(39.7-112.8)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.8	nc	(nc-nc)
Male	3	4.3	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	4	4.1	nc	(nc-nc)
Male	1	3.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.8	nc	(nc-nc)	Female	5	5.5	91.5	(29.5-213.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.7	nc	(nc-nc)	Male	84	97.3	86.3	(68.9-106.9)
Female	0	0.7	nc	(nc-nc)	Female	79	82.6	95.6	(75.7-119.2)
<u>Lung and Bronchus</u>									
Male	12	14.6	82.1	(42.3-143.3)					
Female	13	12.0	108.6	(57.8-185.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oakham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	2	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	8	8.0	100.0	(43.1-197.1)	Female	2	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	0	2.3	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.8	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.1	nc	(nc-nc)	Male	8	7.3	109.6	(47.2-215.9)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.5	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	4	1.6	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.5	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	0.9	nc	(nc-nc)	Male	26	28.6	90.9	(59.4-133.2)
Female	0	0.2	nc	(nc-nc)	Female	27	25.3	106.7	(70.3-155.3)
<u>Lung and Bronchus</u>									
Male	7	3.8	185.5	(74.3-382.1)					
Female	1	3.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Orange

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	9.1	88.1	(37.9-173.6)	Male	1	5.9	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	3	4.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.7	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	5	1.4	348.9	(112.4-814.3)	Female	2	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.3	95.1	(30.6-221.9)
Female	32	37.9	84.4	(57.7-119.1)	Female	6	4.3	141.0	(51.5-307.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	7	4.5	155.0	(62.1-319.3)
<u>Colon / Rectum</u>					Female	3	2.0	nc	(nc-nc)
Male	5	9.6	52.1	(16.8-121.6)	<u>Ovary</u>				
Female	8	8.7	92.5	(39.8-182.2)	Female	2	3.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.4	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	25	28.8	86.7	(56.1-127.9)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.2	nc	(nc-nc)
Male	6	5.4	110.1	(40.2-239.7)	Female	0	1.2	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.1	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.4	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	5	6.9	72.3	(23.3-168.7)
Male	4	3.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.5	nc	(nc-nc)	Female	10	8.8	113.7	(54.4-209.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.4	nc	(nc-nc)	Male	110	118.7	92.7	(76.2-111.7)
Female	1	1.0	nc	(nc-nc)	Female	117	120.5	97.1	(80.3-116.3)
<u>Lung and Bronchus</u>									
Male	21	16.4	128.0	(79.2-195.7)					
Female	17	16.2	105.1	(61.2-168.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Orleans

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	15.5	77.2	(39.8-134.9)	Male	21	8.6	242.8	(150.3-371.2)
Female	6	5.0	118.9	(43.4-258.9)	Female	9	5.5	163.8	(74.7-310.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.1	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	13	7.5	172.5	(91.8-295.1)
Female	66	46.5	142.1	(109.9-180.7)	Female	7	6.3	111.3	(44.6-229.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	5	5.5	90.8	(29.3-212.0)
<u>Colon / Rectum</u>					Female	5	2.7	184.6	(59.5-430.8)
Male	14	13.7	102.1	(55.7-171.2)	<u>Ovary</u>				
Female	12	13.1	91.3	(47.1-159.5)	Female	6	4.1	146.9	(53.7-319.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.6	nc	(nc-nc)	Male	5	5.3	94.2	(30.4-219.8)
Female	0	1.0	nc	(nc-nc)	Female	8	5.3	151.9	(65.4-299.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	36	40.8	88.3	(61.9-122.3)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.4	nc	(nc-nc)
Male	4	7.1	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
Female	1	4.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	3	5.9	nc	(nc-nc)
Male	7	5.2	133.4	(53.4-274.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.5	nc	(nc-nc)	Female	7	11.2	62.7	(25.1-129.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	4.4	113.7	(36.7-265.4)	Male	160	172.9	92.5	(78.7-108.0)
Female	0	1.6	nc	(nc-nc)	Female	180	164.0	109.7	(94.3-127.0)
<u>Lung and Bronchus</u>									
Male	10	27.3	36.6	(17.5-67.3)					
Female	18	26.6	67.7	(40.1-107.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Otis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	2.8	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	13	8.5	153.2	(81.5-262.1)	Female	3	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	<u>Ovary</u>				
Female	2	2.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	8.8	56.8	(18.3-132.6)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.7	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.4	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.6	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.0	nc	(nc-nc)	Male	18	35.6	50.5	(29.9-79.8)
Female	0	0.3	nc	(nc-nc)	Female	29	28.3	102.4	(68.5-147.0)
<u>Lung and Bronchus</u>									
Male	5	5.2	96.1	(31.0-224.3)					
Female	5	4.3	117.0	(37.7-273.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	11.1	171.4	(103.1-267.7)	Male	11	7.9	139.8	(69.7-250.2)
Female	6	4.8	124.6	(45.5-271.2)	Female	10	7.4	136.0	(65.1-250.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.6	nc	(nc-nc)	Male	8	2.5	314.9	(135.6-620.6)
Female	1	2.4	nc	(nc-nc)	Female	5	2.3	217.5	(70.1-507.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	11	7.0	157.3	(78.4-281.5)
Female	57	58.5	97.4	(73.7-126.1)	Female	9	6.9	130.2	(59.4-247.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.0	nc	(nc-nc)	Male	10	6.5	153.1	(73.3-281.6)
<u>Colon / Rectum</u>					Female	4	3.1	nc	(nc-nc)
Male	10	12.8	78.4	(37.5-144.2)	<u>Ovary</u>				
Female	18	14.2	126.7	(75.1-200.3)	Female	9	5.0	179.8	(82.0-341.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.2	nc	(nc-nc)	Male	5	4.4	112.9	(36.4-263.5)
Female	2	0.9	nc	(nc-nc)	Female	6	5.0	120.1	(43.9-261.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	43	41.3	104.1	(75.3-140.2)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.8	nc	(nc-nc)
Male	6	7.9	76.4	(27.9-166.2)	Female	3	2.0	nc	(nc-nc)
Female	9	4.6	196.9	(89.8-373.7)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.1	nc	(nc-nc)
Male	5	1.9	262.1	(84.5-611.7)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	8	3.8	212.3	(91.4-418.3)
<u>Leukemia</u>					Female	14	11.7	119.6	(65.3-200.6)
Male	10	4.9	202.9	(97.1-373.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	4.1	145.0	(53.0-315.6)	Female	22	13.2	166.5	(104.3-252.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	4.7	148.8	(59.6-306.7)	Male	203	161.0	126.1	(109.3-144.7)
Female	2	1.7	nc	(nc-nc)	Female	230	191.7	120.0	(105.0-136.5)
<u>Lung and Bronchus</u>									
Male	29	20.7	140.4	(94.0-201.6)					
Female	25	25.3	98.7	(63.9-145.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Palmer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	13.3	128.0	(74.5-205.0)	Male	13	8.8	148.5	(79.0-254.0)
Female	8	5.4	149.1	(64.2-293.9)	Female	7	7.2	96.8	(38.8-199.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	2.6	269.5	(108.0-555.3)	Male	2	2.8	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	6	7.7	77.9	(28.4-169.6)
Female	63	59.5	105.8	(81.3-135.4)	Female	8	7.3	110.0	(47.4-216.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.8	nc	(nc-nc)	Male	6	6.7	89.0	(32.5-193.7)
<u>Colon / Rectum</u>					Female	2	3.3	nc	(nc-nc)
Male	12	14.3	83.9	(43.3-146.5)	<u>Ovary</u>				
Female	13	14.9	87.0	(46.3-148.8)	Female	8	5.1	157.4	(67.8-310.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.5	nc	(nc-nc)	Male	4	5.0	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	7	5.7	123.8	(49.6-255.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	32	42.1	76.1	(52.0-107.4)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	3.2	188.7	(68.9-410.7)
Male	14	8.1	173.3	(94.7-290.8)	Female	3	2.1	nc	(nc-nc)
Female	6	4.8	125.9	(46.0-274.0)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.9	nc	(nc-nc)
Male	4	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	1	3.6	nc	(nc-nc)
<u>Leukemia</u>					Female	7	10.3	67.7	(27.1-139.5)
Male	5	5.4	92.7	(29.9-216.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.2	nc	(nc-nc)	Female	8	14.0	57.3	(24.7-113.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	4.9	101.2	(32.6-236.1)	Male	183	174.6	104.8	(90.2-121.1)
Female	2	1.8	nc	(nc-nc)	Female	186	199.4	93.3	(80.4-107.7)
<u>Lung and Bronchus</u>									
Male	29	23.8	121.7	(81.5-174.8)					
Female	20	28.5	70.1	(42.8-108.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Paxton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	5.8	137.2	(59.1-270.4)	Male	5	3.7	135.3	(43.6-315.6)
Female	2	1.7	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.1	nc	(nc-nc)	Male	3	1.2	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.2	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	19	21.0	90.5	(54.5-141.4)	Female	2	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.1	nc	(nc-nc)
Male	1	6.1	nc	(nc-nc)	<u>Ovary</u>				
Female	3	4.9	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.5	nc	(nc-nc)	Male	4	2.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	22	18.4	119.3	(74.8-180.7)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.4	nc	(nc-nc)
Male	4	3.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	2	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	3.8	nc	(nc-nc)
Male	5	2.3	213.7	(68.9-498.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.4	nc	(nc-nc)	Female	7	5.0	141.2	(56.6-290.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.1	nc	(nc-nc)	Male	79	75.0	105.3	(83.4-131.2)
Female	0	0.6	nc	(nc-nc)	Female	52	68.1	76.4	(57.0-100.2)
<u>Lung and Bronchus</u>									
Male	5	10.3	48.8	(15.7-113.8)					
Female	4	9.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peabody

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	100	73.3	136.4	(110.9-165.8)	Male	41	43.9	93.3	(66.9-126.6)
Female	38	28.0	135.6	(96.0-186.2)	Female	33	34.3	96.1	(66.1-134.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	12.0	58.1	(23.3-119.8)	Male	21	14.3	147.4	(91.2-225.3)
Female	15	10.9	137.1	(76.7-226.1)	Female	14	12.5	111.7	(61.0-187.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.4	nc	(nc-nc)	Male	41	38.9	105.5	(75.7-143.1)
Female	294	269.0	109.3	(97.2-122.5)	Female	60	36.2	165.8	(126.5-213.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	11	8.2	134.3	(67.0-240.4)	Male	28	30.0	93.2	(61.9-134.7)
<u>Colon / Rectum</u>					Female	17	15.5	109.5	(63.8-175.3)
Male	63	72.0	87.5	(67.2-112.0)	<u>Ovary</u>				
Female	79	78.9	100.2	(79.3-124.8)	Female	20	23.9	83.8	(51.2-129.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	17.2	81.3	(44.4-136.4)	Male	26	25.9	100.4	(65.6-147.1)
Female	3	5.3	nc	(nc-nc)	Female	27	29.7	91.0	(60.0-132.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	4.2	nc	(nc-nc)	Male	200	194.0	103.1	(89.3-118.4)
Female	4	3.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	17	16.4	103.5	(60.2-165.7)
Male	36	37.1	97.0	(68.0-134.4)	Female	8	11.1	71.8	(30.9-141.6)
Female	14	22.4	62.5	(34.1-104.9)	<u>Testis</u>				
<u>Larynx</u>					Male	7	7.3	95.9	(38.4-197.6)
Male	18	9.8	183.3	(108.5-289.6)	<u>Thyroid</u>				
Female	1	3.1	nc	(nc-nc)	Male	12	15.2	79.2	(40.9-138.3)
<u>Leukemia</u>					Female	50	44.4	112.6	(83.6-148.5)
Male	30	27.7	108.4	(73.1-154.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	29	21.5	134.9	(90.3-193.7)	Female	45	60.3	74.6	(54.4-99.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	16	23.2	69.1	(39.5-112.2)	Male	898	861.4	104.3	(97.5-111.3)
Female	12	8.8	135.9	(70.1-237.3)	Female	1022	950.2	107.6	(101.1-114.4)
<u>Lung and Bronchus</u>									
Male	124	124.1	99.9	(83.1-119.1)					
Female	153	139.7	109.5	(92.8-128.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pelham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.0	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	4	7.8	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	<u>Ovary</u>				
Female	0	2.0	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	6.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.2	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	0.7	nc	(nc-nc)	Male	18	25.1	71.7	(42.5-113.3)
Female	1	0.2	nc	(nc-nc)	Female	16	26.1	61.3	(35.0-99.6)
<u>Lung and Bronchus</u>									
Male	2	3.5	nc	(nc-nc)					
Female	3	3.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pembroke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	17.8	107.0	(64.4-167.1)	Male	11	12.1	90.7	(45.2-162.2)
Female	6	6.1	98.1	(35.8-213.5)	Female	15	9.6	156.3	(87.4-257.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.7	134.1	(43.2-312.9)	Male	2	3.9	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	13	10.7	121.6	(64.7-207.9)
Female	76	79.4	95.8	(75.4-119.9)	Female	7	9.1	77.2	(30.9-159.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.7	nc	(nc-nc)	Male	11	9.8	111.8	(55.7-200.1)
<u>Colon / Rectum</u>					Female	3	4.1	nc	(nc-nc)
Male	28	19.7	141.9	(94.3-205.1)	<u>Ovary</u>				
Female	18	18.2	99.1	(58.7-156.7)	Female	5	6.7	74.9	(24.1-174.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	4.9	141.6	(56.7-291.8)	Male	7	6.9	101.2	(40.6-208.6)
Female	0	1.2	nc	(nc-nc)	Female	4	6.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.5	nc	(nc-nc)	Male	59	61.5	95.9	(73.0-123.7)
Female	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	4.4	160.0	(64.1-329.6)
Male	17	11.6	146.1	(85.0-233.9)	Female	1	2.6	nc	(nc-nc)
Female	7	6.1	115.6	(46.3-238.2)	<u>Testis</u>				
<u>Larynx</u>					Male	5	2.8	178.3	(57.5-416.2)
Male	3	2.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	7	5.4	129.1	(51.7-266.0)
<u>Leukemia</u>					Female	26	15.4	168.4	(110.0-246.8)
Male	7	7.5	93.9	(37.6-193.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	5.1	116.8	(42.6-254.2)	Female	19	18.3	103.6	(62.3-161.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	7.1	nc	(nc-nc)	Male	273	245.3	111.3	(98.5-125.3)
Female	1	2.2	nc	(nc-nc)	Female	261	252.9	103.2	(91.1-116.5)
<u>Lung and Bronchus</u>									
Male	39	32.2	121.3	(86.2-165.8)					
Female	42	32.9	127.8	(92.1-172.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pepperell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	12.0	91.7	(45.7-164.1)	Male	4	8.1	nc	(nc-nc)
Female	3	4.0	nc	(nc-nc)	Female	5	6.3	78.9	(25.4-184.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.5	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	7.2	69.6	(22.4-162.3)
Female	49	53.1	92.2	(68.2-121.9)	Female	3	5.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.8	nc	(nc-nc)	Male	6	6.6	91.2	(33.3-198.4)
<u>Colon / Rectum</u>					Female	1	2.7	nc	(nc-nc)
Male	15	13.4	111.7	(62.5-184.2)	<u>Ovary</u>				
Female	16	11.9	134.4	(76.8-218.3)	Female	5	4.4	113.0	(36.4-263.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.3	151.5	(48.8-353.5)	Male	6	4.7	128.9	(47.1-280.7)
Female	0	0.8	nc	(nc-nc)	Female	2	4.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	23	40.6	56.6	(35.9-84.9)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.9	nc	(nc-nc)
Male	7	7.8	89.6	(35.9-184.7)	Female	0	1.7	nc	(nc-nc)
Female	6	4.0	148.5	(54.2-323.1)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.7	nc	(nc-nc)
Male	3	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	6	3.5	169.6	(61.9-369.3)
<u>Leukemia</u>					Female	9	10.5	86.1	(39.3-163.4)
Male	4	5.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.4	nc	(nc-nc)	Female	16	12.0	133.5	(76.3-216.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.7	nc	(nc-nc)	Male	142	164.0	86.6	(72.9-102.0)
Female	0	1.4	nc	(nc-nc)	Female	151	167.7	90.1	(76.3-105.6)
<u>Lung and Bronchus</u>									
Male	24	21.7	110.6	(70.8-164.6)					
Female	16	21.9	73.1	(41.8-118.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peru

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	3.8	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.8	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.4	nc	(nc-nc)	Male	10	13.4	74.8	(35.8-137.6)
Female	0	0.1	nc	(nc-nc)	Female	2	11.8	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	1.8	nc	(nc-nc)					
Female	0	1.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Petersham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	1.8	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	5	6.6	76.0	(24.5-177.3)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	3	1.9	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.4	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	5.1	98.8	(31.8-230.6)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.1	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.6	nc	(nc-nc)	Male	21	21.2	99.0	(61.2-151.3)
Female	1	0.2	nc	(nc-nc)	Female	13	21.9	59.4	(31.6-101.6)
<u>Lung and Bronchus</u>									
Male	1	2.9	nc	(nc-nc)					
Female	1	3.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Phillipston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	3	8.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.4	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	9	5.9	153.0	(69.8-290.4)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.4	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.7	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.7	nc	(nc-nc)	Male	26	22.5	115.7	(75.5-169.5)
Female	0	0.2	nc	(nc-nc)	Female	15	25.3	59.3	(33.1-97.8)
<u>Lung and Bronchus</u>									
Male	4	2.8	nc	(nc-nc)					
Female	3	3.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pittsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	72	55.8	129.1	(101.0-162.5)	Male	29	34.4	84.3	(56.4-121.1)
Female	24	20.4	117.5	(75.2-174.8)	Female	21	26.7	78.6	(48.6-120.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	9.8	132.5	(70.5-226.6)	Male	8	11.1	72.1	(31.0-142.0)
Female	6	8.6	69.5	(25.4-151.4)	Female	2	9.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.9	nc	(nc-nc)	Male	30	30.4	98.7	(66.6-140.9)
Female	206	214.1	96.2	(83.5-110.3)	Female	27	27.2	99.2	(65.3-144.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	6.6	75.9	(24.5-177.2)	Male	33	24.9	132.8	(91.4-186.5)
<u>Colon / Rectum</u>					Female	12	11.9	100.5	(51.8-175.5)
Male	61	56.5	108.0	(82.6-138.8)	<u>Ovary</u>				
Female	85	57.2	148.7	(118.8-183.8)	Female	16	18.7	85.5	(48.8-138.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	24	13.7	175.6	(112.5-261.3)	Male	20	20.2	99.0	(60.4-152.9)
Female	5	3.9	126.6	(40.8-295.5)	Female	25	21.3	117.3	(75.9-173.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	3.6	139.5	(45.0-325.6)	Male	157	162.5	96.6	(82.1-113.0)
Female	1	3.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	14	12.8	109.4	(59.8-183.6)
Male	33	30.4	108.7	(74.8-152.7)	Female	8	8.1	99.1	(42.7-195.2)
Female	25	17.5	142.9	(92.4-210.9)	<u>Testis</u>				
<u>Larynx</u>					Male	8	6.4	124.5	(53.6-245.3)
Male	9	7.9	114.4	(52.2-217.3)	<u>Thyroid</u>				
Female	1	2.5	nc	(nc-nc)	Male	10	12.7	78.5	(37.6-144.3)
<u>Leukemia</u>					Female	33	37.1	89.0	(61.3-125.0)
Male	23	21.7	106.1	(67.3-159.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	16.1	62.3	(29.8-114.6)	Female	67	49.1	136.4	(105.7-173.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	20	18.7	107.0	(65.3-165.3)	Male	746	686.6	108.7	(101.0-116.7)
Female	6	6.7	90.0	(32.9-195.9)	Female	771	732.7	105.2	(97.9-112.9)
<u>Lung and Bronchus</u>									
Male	117	96.3	121.5	(100.4-145.6)					
Female	131	106.3	123.3	(103.1-146.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plainfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	4	3.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.3	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	7	12.8	54.7	(21.9-112.7)
Female	0	0.1	nc	(nc-nc)	Female	13	11.0	118.2	(62.9-202.1)
<u>Lung and Bronchus</u>									
Male	0	1.8	nc	(nc-nc)					
Female	5	1.6	320.4	(103.3-747.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plainville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	7.7	116.3	(53.1-220.7)	Male	7	5.5	127.1	(50.9-262.0)
Female	2	3.2	nc	(nc-nc)	Female	3	4.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.7	nc	(nc-nc)	Male	4	1.8	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.3	nc	(nc-nc)	Male	7	4.9	143.3	(57.4-295.3)
Female	39	37.3	104.5	(74.3-142.8)	Female	1	4.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	2.0	nc	(nc-nc)
Male	10	9.2	108.9	(52.1-200.3)	<u>Ovary</u>				
Female	8	9.3	86.2	(37.1-169.9)	Female	4	3.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.2	nc	(nc-nc)	Male	6	3.1	195.0	(71.2-424.4)
Female	0	0.6	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	32	27.3	117.3	(80.2-165.6)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.0	nc	(nc-nc)
Male	12	5.4	222.8	(115.0-389.2)	Female	0	1.3	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.5	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<u>Leukemia</u>					Female	7	7.4	94.9	(38.0-195.6)
Male	5	3.4	148.8	(47.9-347.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	2.6	226.9	(82.8-493.9)	Female	9	8.3	107.9	(49.2-204.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.1	nc	(nc-nc)	Male	139	110.4	125.9	(105.9-148.7)
Female	0	1.1	nc	(nc-nc)	Female	119	123.1	96.7	(80.1-115.7)
<u>Lung and Bronchus</u>									
Male	23	14.0	164.7	(104.4-247.2)					
Female	17	16.5	102.7	(59.8-164.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	67	68.6	97.6	(75.6-124.0)	Male	76	44.6	170.2	(134.1-213.1)
Female	27	24.9	108.3	(71.4-157.6)	Female	50	34.4	145.3	(107.9-191.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	13.1	91.6	(47.3-160.0)	Male	10	14.5	68.9	(33.0-126.8)
Female	11	11.1	99.3	(49.5-177.7)	Female	11	11.8	93.4	(46.5-167.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.5	nc	(nc-nc)	Male	50	39.4	126.8	(94.1-167.2)
Female	305	288.0	105.9	(94.4-118.5)	Female	27	34.3	78.7	(51.8-114.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	9.0	66.7	(24.4-145.2)	Male	34	34.2	99.3	(68.8-138.8)
<u>Colon / Rectum</u>					Female	20	15.5	129.0	(78.7-199.2)
Male	60	71.8	83.6	(63.8-107.6)	<u>Ovary</u>				
Female	56	70.0	80.0	(60.4-103.9)	Female	33	24.4	135.0	(92.9-189.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	18	18.1	99.5	(58.9-157.3)	Male	27	26.0	104.0	(68.5-151.3)
Female	1	5.0	nc	(nc-nc)	Female	21	26.0	80.8	(50.0-123.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	4.9	nc	(nc-nc)	Male	229	225.1	101.8	(89.0-115.8)
Female	2	3.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	14	16.3	85.7	(46.8-143.8)
Male	43	41.6	103.4	(74.8-139.3)	Female	12	9.8	122.2	(63.1-213.5)
Female	22	22.8	96.4	(60.4-145.9)	<u>Testis</u>				
<u>Larynx</u>					Male	9	8.8	102.3	(46.7-194.1)
Male	9	10.6	84.6	(38.6-160.5)	<u>Thyroid</u>				
Female	1	3.3	nc	(nc-nc)	Male	22	18.1	121.7	(76.2-184.2)
<u>Leukemia</u>					Female	72	50.2	143.4	(112.2-180.6)
Male	28	27.5	101.7	(67.6-147.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	16	19.6	81.6	(46.6-132.5)	Female	79	67.3	117.3	(92.9-146.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	30	25.2	118.9	(80.2-169.7)	Male	961	903.4	106.4	(99.8-113.3)
Female	7	8.4	83.6	(33.5-172.3)	Female	1006	947.9	106.1	(99.7-112.9)
<u>Lung and Bronchus</u>									
Male	127	124.5	102.0	(85.0-121.4)					
Female	148	134.8	109.8	(92.8-129.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plympton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.8	132.4	(42.7-308.9)	Male	1	2.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.7	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	14	12.7	110.0	(60.1-184.7)	Female	1	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	0.7	nc	(nc-nc)
Male	3	3.9	nc	(nc-nc)	<u>Ovary</u>				
Female	4	2.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.0	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	15	12.8	117.5	(65.7-193.8)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.9	nc	(nc-nc)
Male	3	2.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	3	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.4	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.8	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.4	nc	(nc-nc)	Male	46	50.1	91.9	(67.3-122.6)
Female	0	0.4	nc	(nc-nc)	Female	49	40.1	122.1	(90.3-161.4)
<u>Lung and Bronchus</u>									
Male	2	6.9	nc	(nc-nc)					
Female	7	5.4	129.6	(51.9-267.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Princeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.5	141.2	(45.5-329.5)	Male	6	2.5	240.4	(87.8-523.2)
Female	0	1.2	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	0.8	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	21	17.0	123.5	(76.4-188.7)	Female	1	1.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	11	2.2	508.0	(253.2-908.9)
<u>Colon / Rectum</u>					Female	0	0.9	nc	(nc-nc)
Male	5	4.1	122.8	(39.6-286.5)	<u>Ovary</u>				
Female	2	3.4	nc	(nc-nc)	Female	5	1.4	359.5	(115.9-838.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	11	13.8	79.8	(39.8-142.8)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.9	nc	(nc-nc)
Male	4	2.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	2	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	3	3.1	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.0	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.6	nc	(nc-nc)	Male	63	51.9	121.5	(93.3-155.4)
Female	0	0.5	nc	(nc-nc)	Female	50	52.3	95.6	(70.9-126.0)
<u>Lung and Bronchus</u>									
Male	1	6.7	nc	(nc-nc)					
Female	3	7.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Provincetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	6.2	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
Female	7	2.1	329.5	(132.0-679.0)	Female	5	2.4	205.2	(66.1-478.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.0	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
Female	23	21.0	109.8	(69.6-164.7)	Female	1	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	7	2.8	246.5	(98.7-507.8)
<u>Colon / Rectum</u>					Female	4	1.2	nc	(nc-nc)
Male	4	6.3	nc	(nc-nc)	<u>Ovary</u>				
Female	11	5.5	199.6	(99.5-357.1)	Female	4	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.6	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	10	19.4	51.6	(24.7-94.9)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.4	nc	(nc-nc)
Male	5	3.4	146.0	(47.1-340.8)	Female	0	0.8	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.7	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.5	nc	(nc-nc)	Female	4	5.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.1	nc	(nc-nc)	Male	66	76.7	86.1	(66.6-109.5)
Female	0	0.7	nc	(nc-nc)	Female	88	72.0	122.3	(98.1-150.7)
<u>Lung and Bronchus</u>									
Male	11	10.9	101.3	(50.5-181.2)					
Female	11	11.4	96.3	(48.0-172.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Quincy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	100	95.9	104.3	(84.9-126.9)	Male	57	62.1	91.8	(69.6-119.0)
Female	35	36.0	97.2	(67.7-135.2)	Female	55	50.0	110.0	(82.9-143.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	19	18.8	100.8	(60.7-157.4)	Male	14	19.7	71.1	(38.9-119.4)
Female	17	16.2	105.0	(61.1-168.1)	Female	14	16.6	84.5	(46.1-141.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	5	3.4	149.1	(48.1-348.0)	Male	50	55.1	90.7	(67.3-119.5)
Female	400	389.7	102.6	(92.8-113.2)	Female	57	49.0	116.4	(88.2-150.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	21	12.8	164.7	(101.9-251.8)	Male	61	45.2	135.0	(103.3-173.4)
<u>Colon / Rectum</u>					Female	29	21.6	134.2	(89.9-192.7)
Male	125	100.6	124.3	(103.5-148.1)	<u>Ovary</u>				
Female	103	102.4	100.6	(82.1-122.0)	Female	34	34.3	99.0	(68.6-138.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	23	24.0	95.9	(60.8-143.9)	Male	30	35.4	84.9	(57.2-121.1)
Female	8	6.9	115.7	(49.8-227.9)	Female	29	37.4	77.5	(51.9-111.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	10	8.2	122.5	(58.7-225.4)	Male	257	281.8	91.2	(80.4-103.1)
Female	10	7.1	140.5	(67.3-258.4)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	30	22.5	133.5	(90.0-190.5)
Male	53	55.1	96.2	(72.1-125.9)	Female	17	14.3	118.6	(69.0-189.9)
Female	34	31.7	107.1	(74.2-149.7)	<u>Testis</u>				
<u>Larynx</u>					Male	17	16.2	105.2	(61.3-168.5)
Male	18	14.0	128.4	(76.1-202.9)	<u>Thyroid</u>				
Female	4	4.4	nc	(nc-nc)	Male	36	25.7	140.2	(98.2-194.2)
<u>Leukemia</u>					Female	65	74.2	87.5	(67.6-111.6)
Male	23	39.2	58.6	(37.1-88.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	30	29.2	102.6	(69.2-146.5)	Female	87	89.0	97.8	(78.3-120.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	57	33.6	169.6	(128.4-219.7)	Male	1316	1222.0	107.7	(102.0-113.7)
Female	17	11.9	142.5	(83.0-228.2)	Female	1406	1330.3	105.7	(100.2-111.4)
<u>Lung and Bronchus</u>									
Male	237	167.4	141.6	(124.1-160.8)					
Female	241	188.2	128.0	(112.4-145.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Randolph

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	33	34.7	95.0	(65.4-133.4)	Male	12	22.4	53.5	(27.6-93.5)
Female	11	14.1	78.0	(38.9-139.6)	Female	13	19.6	66.4	(35.3-113.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	6.7	119.3	(51.4-235.0)	Male	8	7.2	111.4	(48.0-219.5)
Female	5	6.3	79.0	(25.4-184.3)	Female	7	6.6	105.7	(42.3-217.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.2	nc	(nc-nc)	Male	12	19.9	60.2	(31.1-105.2)
Female	145	157.0	92.4	(78.0-108.7)	Female	22	19.5	113.1	(70.8-171.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	5.1	nc	(nc-nc)	Male	9	17.1	52.7	(24.0-100.0)
<u>Colon / Rectum</u>					Female	6	8.6	69.7	(25.4-151.6)
Male	35	37.1	94.2	(65.6-131.1)	<u>Ovary</u>				
Female	46	40.1	114.8	(84.0-153.1)	Female	11	13.6	81.0	(40.4-145.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	8.9	90.2	(38.8-177.7)	Male	10	12.9	77.2	(37.0-142.1)
Female	2	2.8	nc	(nc-nc)	Female	10	14.7	67.9	(32.5-124.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.7	nc	(nc-nc)	Male	101	107.4	94.1	(76.6-114.3)
Female	2	2.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	8.2	122.0	(58.4-224.3)
Male	29	20.5	141.6	(94.8-203.3)	Female	6	5.7	106.1	(38.7-230.9)
Female	8	12.6	63.7	(27.4-125.5)	<u>Testis</u>				
<u>Larynx</u>					Male	0	5.0	nc	(nc-nc)
Male	7	5.1	136.8	(54.8-282.0)	<u>Thyroid</u>				
Female	1	1.8	nc	(nc-nc)	Male	13	9.2	141.4	(75.2-241.7)
<u>Leukemia</u>					Female	35	28.9	121.1	(84.3-168.4)
Male	11	14.1	77.9	(38.8-139.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	11.3	nc	(nc-nc)	Female	41	36.3	113.0	(81.1-153.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	15	12.5	119.9	(67.1-197.8)	Male	391	448.5	87.2	(78.8-96.3)
Female	1	4.7	nc	(nc-nc)	Female	461	527.4	87.4	(79.6-95.8)
<u>Lung and Bronchus</u>									
Male	44	60.2	73.1	(53.1-98.1)					
Female	52	73.7	70.6	(52.7-92.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Raynham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	14.5	89.5	(47.6-153.1)	Male	11	9.6	114.6	(57.2-205.1)
Female	6	5.7	105.7	(38.6-230.0)	Female	11	7.8	141.1	(70.4-252.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.9	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	12	8.4	143.0	(73.8-249.8)
Female	69	63.2	109.3	(85.0-138.3)	Female	7	7.8	89.9	(36.0-185.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.0	nc	(nc-nc)	Male	5	7.5	67.0	(21.6-156.4)
<u>Colon / Rectum</u>					Female	4	3.4	nc	(nc-nc)
Male	26	15.7	165.9	(108.4-243.1)	<u>Ovary</u>				
Female	17	15.9	107.1	(62.3-171.5)	Female	9	5.4	166.5	(76.0-316.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	3.8	157.8	(57.6-343.4)	Male	5	5.5	90.8	(29.3-211.8)
Female	1	1.1	nc	(nc-nc)	Female	5	5.8	85.6	(27.6-199.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.1	nc	(nc-nc)	Male	48	46.6	102.9	(75.9-136.5)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.5	nc	(nc-nc)
Male	12	8.9	135.5	(69.9-236.7)	Female	1	2.2	nc	(nc-nc)
Female	6	5.1	118.2	(43.2-257.3)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.0	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	6	3.9	153.2	(55.9-333.5)
<u>Leukemia</u>					Female	24	11.5	208.2	(133.4-309.9)
Male	2	6.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.5	nc	(nc-nc)	Female	16	14.3	112.1	(64.1-182.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	5.5	108.4	(39.6-236.0)	Male	213	191.8	111.1	(96.6-127.0)
Female	2	1.9	nc	(nc-nc)	Female	238	211.5	112.5	(98.7-127.8)
<u>Lung and Bronchus</u>									
Male	23	26.0	88.5	(56.1-132.7)					
Female	26	30.4	85.4	(55.8-125.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	25.7	101.2	(66.1-148.2)	Male	14	16.7	83.8	(45.8-140.6)
Female	11	10.3	106.8	(53.2-191.1)	Female	15	14.3	104.9	(58.7-173.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	5.0	nc	(nc-nc)	Male	4	5.3	nc	(nc-nc)
Female	6	4.6	130.2	(47.5-283.4)	Female	2	4.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	17	14.8	114.6	(66.7-183.5)
Female	129	112.7	114.5	(95.6-136.0)	Female	8	14.0	57.0	(24.6-112.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.8	nc	(nc-nc)	Male	14	12.7	110.1	(60.2-184.8)
<u>Colon / Rectum</u>					Female	6	6.2	97.1	(35.4-211.3)
Male	32	27.6	116.0	(79.3-163.8)	<u>Ovary</u>				
Female	27	29.9	90.4	(59.6-131.5)	Female	14	9.7	143.8	(78.6-241.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	6.6	75.9	(24.5-177.1)	Male	9	9.6	94.0	(42.9-178.5)
Female	2	2.0	nc	(nc-nc)	Female	9	10.8	83.0	(37.9-157.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.9	nc	(nc-nc)	Male	66	79.4	83.2	(64.3-105.8)
Female	2	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	6.1	nc	(nc-nc)
Male	16	15.3	104.5	(59.7-169.7)	Female	1	4.2	nc	(nc-nc)
Female	8	9.0	88.7	(38.2-174.7)	<u>Testis</u>				
<u>Larynx</u>					Male	6	3.7	161.0	(58.8-350.5)
Male	1	3.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.2	nc	(nc-nc)	Male	8	7.0	114.0	(49.1-224.6)
<u>Leukemia</u>					Female	25	21.0	119.2	(77.1-175.9)
Male	13	10.6	123.1	(65.5-210.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	8.4	106.8	(48.7-202.7)	Female	24	25.1	95.7	(61.3-142.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	9.3	117.9	(58.8-211.0)	Male	307	332.9	92.2	(82.2-103.1)
Female	4	3.4	nc	(nc-nc)	Female	378	381.0	99.2	(89.5-109.7)
<u>Lung and Bronchus</u>									
Male	32	44.5	72.0	(49.2-101.6)					
Female	37	52.5	70.4	(49.6-97.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rehoboth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	14.9	nc	(nc-nc)	Male	8	9.5	84.2	(36.3-166.0)
Female	5	3.7	134.3	(43.3-313.4)	Female	6	5.9	102.0	(37.2-222.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.7	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	9	8.4	107.0	(48.8-203.2)
Female	51	49.1	103.8	(77.3-136.5)	Female	7	5.5	127.8	(51.2-263.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.7	nc	(nc-nc)	Male	0	7.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	2.6	nc	(nc-nc)
Male	9	15.7	57.2	(26.1-108.7)	<u>Ovary</u>				
Female	9	10.8	83.7	(38.2-158.8)	Female	4	4.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.8	nc	(nc-nc)	Male	1	5.5	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	3.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	35	45.9	76.2	(53.1-106.0)
Female	2	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.5	nc	(nc-nc)
Male	7	8.6	81.0	(32.5-166.9)	Female	0	1.5	nc	(nc-nc)
Female	5	3.8	132.9	(42.8-310.2)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.8	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.5	nc	(nc-nc)	Male	0	3.7	nc	(nc-nc)
<u>Leukemia</u>					Female	10	9.6	104.3	(49.9-191.8)
Male	5	5.9	84.8	(27.3-197.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.2	nc	(nc-nc)	Female	16	11.7	137.3	(78.4-223.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	5.4	nc	(nc-nc)	Male	124	190.2	65.2	(54.2-77.7)
Female	1	1.4	nc	(nc-nc)	Female	154	156.0	98.7	(83.8-115.6)
<u>Lung and Bronchus</u>									
Male	24	25.8	92.9	(59.5-138.2)					
Female	17	20.4	83.3	(48.5-133.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Revere

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	52	52.2	99.5	(74.3-130.5)	Male	18	34.9	51.6	(30.5-81.5)
Female	18	19.8	90.9	(53.8-143.7)	Female	20	27.4	73.1	(44.6-112.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	10.9	64.2	(25.7-132.4)	Male	7	10.9	64.1	(25.7-132.1)
Female	12	8.9	135.2	(69.8-236.1)	Female	10	9.1	109.4	(52.4-201.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.8	nc	(nc-nc)	Male	30	30.9	97.0	(65.4-138.5)
Female	190	216.0	87.9	(75.9-101.4)	Female	25	27.0	92.7	(60.0-136.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	7.0	71.2	(22.9-166.0)	Male	21	25.8	81.4	(50.4-124.5)
<u>Colon / Rectum</u>					Female	20	11.9	167.8	(102.5-259.2)
Male	60	56.4	106.4	(81.2-137.0)	<u>Ovary</u>				
Female	45	55.5	81.0	(59.1-108.4)	Female	13	18.8	69.2	(36.8-118.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	13.3	67.7	(30.9-128.5)	Male	23	19.5	117.9	(74.7-176.9)
Female	2	3.9	nc	(nc-nc)	Female	16	20.5	77.9	(44.5-126.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	4.9	123.3	(45.0-268.3)	Male	111	156.5	70.9	(58.4-85.4)
Female	10	3.7	267.7	(128.2-492.3)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	20	12.5	160.3	(97.9-247.5)
Male	35	31.4	111.4	(77.6-154.9)	Female	11	7.9	139.5	(69.6-249.7)
Female	24	17.5	136.9	(87.7-203.7)	<u>Testis</u>				
<u>Larynx</u>					Male	7	10.2	68.4	(27.4-141.0)
Male	6	7.8	77.1	(28.2-167.8)	<u>Thyroid</u>				
Female	5	2.5	203.5	(65.6-474.9)	Male	10	15.5	64.5	(30.9-118.6)
<u>Leukemia</u>					Female	53	40.5	130.8	(98.0-171.1)
Male	26	22.0	118.1	(77.1-173.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	17	16.0	106.3	(61.9-170.1)	Female	37	49.7	74.4	(52.4-102.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	24	18.8	127.8	(81.8-190.1)	Male	659	682.7	96.5	(89.3-104.2)
Female	7	6.6	106.5	(42.7-219.5)	Female	734	733.4	100.1	(93.0-107.6)
<u>Lung and Bronchus</u>									
Male	136	91.8	148.2	(124.3-175.3)					
Female	141	104.3	135.1	(113.7-159.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Richmond

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	3.3	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	7	10.1	69.6	(27.9-143.5)	Female	1	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	1	3.1	nc	(nc-nc)	<u>Ovary</u>				
Female	2	2.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	12	9.9	121.2	(62.6-211.7)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.7	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.4	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.7	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.1	nc	(nc-nc)	Male	19	39.6	48.0	(28.9-75.0)
Female	0	0.3	nc	(nc-nc)	Female	17	34.1	49.9	(29.0-79.9)
<u>Lung and Bronchus</u>									
Male	3	5.8	nc	(nc-nc)					
Female	0	5.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rochester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	6.0	83.3	(26.9-194.4)	Male	3	4.0	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)	Female	0	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	26	23.3	111.5	(72.8-163.4)	Female	2	2.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.2	nc	(nc-nc)
Male	4	6.5	nc	(nc-nc)	<u>Ovary</u>				
Female	10	5.5	182.7	(87.4-335.9)	Female	1	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.7	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	26	20.7	125.4	(81.9-183.8)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.5	nc	(nc-nc)
Male	6	3.8	156.4	(57.1-340.4)	Female	1	0.8	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.8	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	3	4.5	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.6	nc	(nc-nc)	Female	4	5.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.4	nc	(nc-nc)	Male	81	81.8	99.1	(78.7-123.1)
Female	0	0.7	nc	(nc-nc)	Female	73	74.6	97.9	(76.7-123.1)
<u>Lung and Bronchus</u>									
Male	9	11.0	81.8	(37.3-155.4)					
Female	6	9.3	64.2	(23.4-139.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	18.5	140.3	(91.6-205.6)	Male	16	12.0	132.8	(75.9-215.7)
Female	9	7.2	124.8	(57.0-236.9)	Female	14	9.8	142.2	(77.7-238.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.7	162.5	(59.3-353.7)	Male	4	3.9	nc	(nc-nc)
Female	4	3.2	nc	(nc-nc)	Female	1	3.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	10	10.8	93.0	(44.5-171.0)
Female	82	80.8	101.5	(80.8-126.0)	Female	18	9.8	183.2	(108.5-289.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.5	nc	(nc-nc)	Male	11	9.0	122.1	(60.9-218.5)
<u>Colon / Rectum</u>					Female	5	4.4	113.8	(36.7-265.5)
Male	26	19.6	132.6	(86.6-194.3)	<u>Ovary</u>				
Female	25	20.1	124.4	(80.5-183.7)	Female	7	6.9	101.0	(40.4-208.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	4.8	208.7	(99.9-383.9)	Male	6	6.9	86.7	(31.6-188.7)
Female	1	1.4	nc	(nc-nc)	Female	11	7.5	146.6	(73.1-262.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.5	nc	(nc-nc)	Male	60	57.8	103.8	(79.2-133.6)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	4.4	nc	(nc-nc)
Male	17	11.0	155.2	(90.3-248.5)	Female	7	2.8	248.6	(99.6-512.1)
Female	15	6.5	231.0	(129.2-381.0)	<u>Testis</u>				
<u>Larynx</u>					Male	2	3.0	nc	(nc-nc)
Male	4	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	3	5.0	nc	(nc-nc)
<u>Leukemia</u>					Female	17	14.2	119.7	(69.7-191.6)
Male	9	7.5	119.4	(54.5-226.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	5.7	139.6	(60.1-275.2)	Female	23	18.8	122.2	(77.4-183.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	6.7	74.5	(24.0-173.9)	Male	276	241.3	114.4	(101.3-128.7)
Female	4	2.4	nc	(nc-nc)	Female	330	269.5	122.4	(109.6-136.4)
<u>Lung and Bronchus</u>									
Male	32	32.8	97.5	(66.6-137.6)					
Female	50	38.7	129.3	(96.0-170.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	12.3	113.4	(62.0-190.4)	Male	5	7.4	68.0	(21.9-158.7)
Female	2	5.0	nc	(nc-nc)	Female	7	5.8	120.5	(48.3-248.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.9	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	3	6.4	nc	(nc-nc)
Female	50	47.9	104.3	(77.4-137.5)	Female	4	6.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	5	5.3	93.8	(30.2-218.8)
<u>Colon / Rectum</u>					Female	5	2.8	181.0	(58.3-422.3)
Male	9	11.9	75.6	(34.5-143.5)	<u>Ovary</u>				
Female	6	13.6	44.2	(16.1-96.2)	Female	5	4.2	119.5	(38.5-278.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.1	nc	(nc-nc)	Male	2	4.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	3	5.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	39	37.1	105.2	(74.8-143.8)
Female	2	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.8	nc	(nc-nc)
Male	10	6.5	154.0	(73.7-283.3)	Female	0	1.9	nc	(nc-nc)
Female	5	4.0	124.7	(40.2-291.0)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
<u>Leukemia</u>					Female	5	6.8	73.9	(23.8-172.5)
Male	6	4.5	134.0	(48.9-291.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.7	nc	(nc-nc)	Female	8	11.2	71.3	(30.7-140.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	4.1	nc	(nc-nc)	Male	137	149.4	91.7	(77.0-108.4)
Female	1	1.6	nc	(nc-nc)	Female	143	167.9	85.2	(71.8-100.4)
<u>Lung and Bronchus</u>									
Male	20	21.7	92.0	(56.2-142.2)					
Female	14	26.0	53.8	(29.4-90.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rowe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	2.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	2	0.7	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	9.4	53.4	(17.2-124.6)
Female	0	0.1	nc	(nc-nc)	Female	2	8.9	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	1.3	nc	(nc-nc)					
Female	0	1.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rowley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	6.7	89.2	(32.6-194.1)	Male	6	4.6	131.1	(47.9-285.3)
Female	6	2.4	252.4	(92.2-549.4)	Female	7	3.6	196.3	(78.7-404.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	4.0	126.1	(40.6-294.2)
Female	31	28.5	108.8	(73.9-154.4)	Female	4	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	1	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.5	nc	(nc-nc)
Male	8	7.4	108.6	(46.7-213.9)	<u>Ovary</u>				
Female	7	7.1	97.9	(39.2-201.8)	Female	4	2.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.8	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	20	22.8	87.7	(53.6-135.5)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.6	nc	(nc-nc)
Male	1	4.3	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.9	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	6	5.6	107.9	(39.4-234.9)
Male	4	2.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	2.0	nc	(nc-nc)	Female	4	6.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.7	nc	(nc-nc)	Male	81	91.6	88.4	(70.2-109.9)
Female	1	0.8	nc	(nc-nc)	Female	94	93.4	100.7	(81.3-123.2)
<u>Lung and Bronchus</u>									
Male	10	12.4	80.8	(38.7-148.7)					
Female	7	12.4	56.5	(22.6-116.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Royalston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.5	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	7	6.2	112.0	(44.9-230.8)	Female	2	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	5	1.7	295.1	(95.1-688.6)	<u>Ovary</u>				
Female	0	1.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	10	5.3	189.2	(90.6-347.9)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.1	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	27	20.8	129.9	(85.6-189.0)
Female	0	0.2	nc	(nc-nc)	Female	17	19.8	85.9	(50.0-137.5)
<u>Lung and Bronchus</u>									
Male	2	2.7	nc	(nc-nc)					
Female	1	2.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;